# Anteris Technologies Ltd. (AVR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $351M  
**Price:** $9.50 (+0.32%)

> Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases. Its flagship product, the DurAVR Transcatheter Heart Valve system, features a single-piece, native-shaped biomimetic design engineered to mimic the performance of a healthy aortic valve, addressing aortic stenosis through minimally invasive procedures. The system incorporates ADAPT anti-calcification tissue, which transforms xenograft material into durable bioscaffolds resembling human tissue, and the ComASUR delivery system, a balloon-expandable mechanism with a reinforced steerable catheter for precise navigation through heart anatomy. Anteris Technologies Ltd. operates across key markets including the United States, Germany, Australia, Switzerland, and Sweden, with a focus on advancing cardiac care via science-driven innovations. Headquartered in Toowong, Australia, the company partners with interventional cardiologists and cardiac surgeons to deliver paradigm-shifting hemodynamic performance and deliverability in transcatheter aortic valve replacement therapies.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2M | $1M | -$94M | -$94M | — |
| 2024 | $3M | $1M | -$78M | -$76M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $23M | $23M | -$93,000 | — | — |
| 2024 | $81M | $18M | $63M | $70M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$78M | $2M | -$80M |
| 2024 | -$61M | $2M | -$64M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AVR)